直播预告 | 直压工艺中针对挑战性API的解决方案

直压工艺中针对挑战性API的解决方案

北京时间：2022年3月10日  周四  16:00-17:30

直播地址：点击注册参与

活动介绍

• 如何把具有较差流动性和可压性的API（如西格列列汀）开发成直压工艺制剂的研究。

• 如何利用Budenheim磷酸盐，将低剂量制剂（如比索洛尔）从制粒工艺（高剪切或流化床制粒）转换为直压工艺。

① Dr. Daniel Zakowiecki – Global Innovation & Application Development Manager Pharma

Daniel Zakowiecki is a pharmaceutical professional with over 19 years of experience in the pharmaceutical industry, including 12 years working for the international generic drug manufacturer – Polpharma (Poland) and over 7 years working for the specialty excipients manufacturer – Budenheim (Germany). His background combines chemistry (MSc), pharmaceutical technology (PhD) and project management. Daniel is still active as a scientist, collaborates with various scientific institutions. He is the author/co-author of more than 30 articles, including 20 published in scientific journals from the Philadelphia List, and co-inventor of 4 inventions, including 2 granted Patents。

② Dr. Tobias Heß – Head of Innovation & Application Development Management Pharma

Tobias Hess has more than 11 years of experience in the field of pharmaceutical excipients, their development, production as well as application. Tobias is currently working as the Head of the Innovation & Application Development Group for Pharmaceutical and Medical Products at Chemische Fabrik Budenheim KG. In his position he’s responsible for the development of Budenheim’s pharma product portfolio and the technical customer interaction. He and his team investigate novel excipients and their applications. Prior to working with Chemische Fabrik Budenheim KG, Tobias held senior roles at JRS Pharma and DFE Pharma – also in the fields of excipients for solid dosage forms. In July 2020 Tobias was appointed as “Member of Member of the Complex Excipients Expert Committee” of the United States Pharmacopeia.

参会方式

图1：邮件正文点击“加入事件”参会